Introduction to the Cholera Vaccine Session

Pablo Sanchez, MD
Chair, Cholera Vaccine Work Group

Advisory Committee on Immunization Practices
January 12, 2022
Cholera vaccine work group members and contributors

**ACIP members**
- Pablo Sanchez (chair)
- Matt Daley (member)

**Ex officio members**
- Bill Alexander (NIH)
- Tina Mongeau (FDA)

**CDC lead**
- Jenn Collins (NCEZID/DFWED)

**ACIP liaisons**
- Carol Baker (IDSA)
- Elizabeth Barnett (ISTM)
- Adam Ratner (AAP)

**Technical advisors**
- Mike Brady
- Ed Ryan (Harvard)
- Mary Wilson (UCSF/Harvard)

**CDC contributors**
- Grace Appiah (NCEZID/DGMQ)
- Bruce Gutelius (NCEZID/DFWED)
- Eric Mintz (NCEZID/DFWED)
- Talia Pindyk (NCEZID/DFWED)
- John Su (NCEZID/DHQ)
- Farrell Tobolowsky (NCEZID/DFWED)

**CDC GRADE consultants**
- Doug Campos-Outcalt
- Rebecca Morgan
Policy topic under consideration by work group

- Should ACIP recommend CVD 103-HgR for children and adolescents aged 2–17 years traveling to an area with active cholera transmission?
Today’s agenda

- Vaxchora Vaccine – Pediatric Dose Development
  - James McCarty, MD (Stanford University, Emergent BioSolutions)
- Evidence to Recommendations: CVD 103-HgR among children and adolescents aged 2–17 years
  - Jennifer Collins, MD, MSc (CDC/NCEZID/DFWED)